Publications by authors named "E M Jaffee"
Background And Aims: Isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma (CCA) is a highly lethal subtype of hepatobiliary cancer that is often resistant to immune checkpoint inhibitor therapies. We evaluated the effects of IDH1-mutations in CCA cells on the tumor immune microenvironment and identify opportunities for therapeutic intervention.
Approach And Results: Analysis of 2,606 human CCA tumors using deconvolution of RNA-sequencing data identified decreased CD8 T cell and increased M2-like tumor-associated macrophage (TAM) infiltration in IDH1-mutant compared to IDH1-wild type tumors.
Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma.
Int J Radiat Oncol Biol Phys
November 2024
Purpose: Local and distant progression remains common following resection of resectable pancreatic ductal adenocarcinoma (PDAC) despite adjuvant multiagent chemotherapy. We report a prospective institutional phase 1 trial incorporating adjuvant GVAX vaccine, low-dose cyclophosphamide (Cy), and stereotactic body radiation therapy (SBRT) followed by FOLFIRINOX (FFX) among patients who underwent resection of high-risk PDAC.
Patients And Methods: The study design was a modified 3+3.
Article Synopsis
- * In a Phase II clinical trial, 27 patients received entinostat followed by nivolumab, resulting in an objective response rate of 11% and a median response duration of over 10 months, although the primary endpoint for overall effectiveness was not reached.
- * The combination treatment led to significant immune profile changes, including increased dendritic cell activity and enhanced inflammatory response, suggesting potential for improving treatment strategies in PDA despite
Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer.
Carcinogenesis
November 2024
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer known for its strong resistance to traditional treatments, partly due to an immune-suppressive tumor environment.
- The review examines two types of vaccination strategies: exogenous vaccines (like whole-cell and peptide vaccines) and in situ vaccination, which uses existing therapies to stimulate the immune response against the tumor.
- While in situ vaccination shows promise in preclinical studies, more research is needed to refine these approaches and enhance anti-tumor immunity in patients with PDA.